FORT LEE, N.J.--(BUSINESS WIRE)--Kedrion Biopharma proudly announces that Koate® Double Viral Inactivation (DVI) Antihemophilic Factor (human) is now being manufactured using a process that further enhances the safety and purity of that product. Koate-DVI is used in the treatment of hemophilia A, a rare, inherited condition characterized by a person’s inability to form effective blood clots following an injury, and by spontaneous bleeding into one’s joints. Koate-DVI belongs to the class of products known as “plasma-derived clotting factors,” all of which are manufactured using human plasma as starting material.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
